To Eat or not to Eat? Provider Recommendations Surrounding Oral Intake Before the 50g OGTT

SummaryIn 8 patients on no oral intake and with parenteral alimentation, administration of cephalosporins with N-methyl-thiotetrazole side chain (moxalactam, cefamandole), was associated with prolongation of prothrombin time, appearance in the circulation of descarboxy-prothrombin (counter immunoelectrophoresis and echis carinatus assay) and diminution of protein C. Acute administration of 10 mg vitamin Ki was followed by the transient appearance of vitamin K1 2,3-epoxide, indicating an impaired hepatocellular regeneration of vitamin K1 from the epoxide. Impaired hepatic vitamin K1 metabolism, tentatively ascribed to the N-methyl-thiotetrazole group, is one (but possibly not the only) cause of bleeding complications and depression of vitamin K1dependent procoagulants in patients treated with the new class of cephalosporins.

Download Full-text

Epiglottoplasty (Biller Method) for Severe Aspiration — To Preserve Phonation Function and Oral Intake —

Nihon Kikan Shokudoka Gakkai Kaiho ◽

10.2468/jbes.67.154 ◽

2016 ◽

Vol 67 (2) ◽

pp. 154-159

Author(s):

M. Kano

Keyword(s):

Oral Intake

Download Full-text

ORAL INTAKE OF PURIFIED AQUEOUS SOLUTION OF OAT ?-GLUCANS HAS NO EFFECT ON GASTRIC MUCOSA HISTOLOGICAL CHANGES IN PATIENTS WITH CHRONIC GASTRITIS: A PILOT PHASE II CLINICAL TRIAL

10.26226/morressier.57c5383cd462b80296c9c8fb ◽

2016 ◽

Author(s):

Rafal Filip

Keyword(s):

Clinical Trial ◽

Aqueous Solution ◽

Gastric Mucosa ◽

Phase Ii ◽

Chronic Gastritis ◽

Oral Intake ◽

Phase Ii Clinical Trial ◽

Pilot Phase ◽

Histological Changes

Download Full-text

Perioperative Management of Patients Receiving New Anticoagulants

Current Pharmaceutical Design ◽

10.2174/1381612825666190709220449 ◽

2019 ◽

Vol 25 (19) ◽

pp. 2149-2157 ◽

Cited By ~ 1

Author(s):

Massimo Lamperti ◽

Andrey Khozenko ◽

Arun Kumar

Keyword(s):

Vitamin K ◽

Elective Surgery ◽

Vitamin K Antagonists ◽

Oral Anticoagulants ◽

Oral Intake ◽

Bleeding Risk ◽

Dietary Vitamin ◽

Reversal Agent ◽

Onset Of Action ◽

Reversal Agents

There is an increased use of oral anticoagulants for the prevention of venous and arterial thrombosis. Vitamin-K antagonists have been used for decades as the main oral anticoagulants but they have the draback a complex therapeutic management, slow onset of action and by a different oral intake caused by dietary vitamin K intake. New non-vitamin K antagonist oral anticoagulants (NOACs) have been developed to overcome the limitations of warfarin. Their management is easier as it requires a fixed daily dose without coagulation monitoring. Although their therapeutic profile is safe, proper attention should be paid in case of unexpected need for the reversal of their coagulation effect and in case a patient needs to have a scheduled surgery. For non-acute cardiac surgery, discontinuation of NOACs should start at least 48 hours prior surgery. Intracranial bleedings associated with NOACs are less dangerous comparing to those warfarin-induced. NOACs need to be stopped ≥24 hours in case of elective surgery for low bleeding-risk procedures and ≥48 hours for high bleeding-risk surgery in patients with normal renal function and 72 hours in case of reduced CrCl < 80. The therapy with NOACs should be resumed from 48 to 72 hours after the procedure depending on the perceived bleeding, type of surgery and thrombotic risks. There are some available NOAC reversal agents acting within 5 to 20 minutes. In case of lack of reversal agent, adequate diuresis, renal replacement therapy and activated charcoal in case of recent ingestion should be considered.

Download Full-text

Nanoparticles and Its Implications in HIV/AIDS Therapy

Current Drug Discovery Technologies ◽

10.2174/1570163816666190620111652 ◽

2020 ◽

Vol 17 (4) ◽

pp. 448-456 ◽

Cited By ~ 1

Author(s):

Victor B. Oti

Keyword(s):

Direct Injection ◽

Oral Intake ◽

Public Health Problem ◽

Antiretroviral Drugs ◽

The Body ◽

Viral Agent ◽

Treatment And Prevention ◽

Prevention And Treatment ◽

Hiv Aids

The use of Antiretroviral drugs in treating HIV/ AIDS patients has enormously increased their life spans with serious disadvantages. The virus infection still remains a public health problem worldwide with no cure and vaccine for the viral agent until now. The use of nanoparticles (NPs) for the treatment and prevention of HIV/AIDS is an emerging technology of the 21st century. NPs are solid and colloid particles with 10 nm to <1000 nm size range; although, less than 200 nm is the recommended size for nanomedical usage. There are NPs with therapeutic capabilities such as liposomes, micelles, dendrimers and nanocapsules. The particle enters the body mainly via oral intake, direct injection and inhalation. It has been proven to have potentials of advancing the prevention and treatment of the viral agent. Certain NPs have been shown to have selftherapeutic activity for the virus in vitro. Strategies that are novel are emerging which can be used to improve nanotechnology, such as genetic treatment and immunotherapy. In this review, nanoparticles, the types and its characteristics in drug delivery were discussed. The light was furthermore shed on its implications in the prevention and treatment of HIV/AIDS.

Download Full-text